Literature DB >> 9817027

Src homology-2 domains: structure, mechanisms, and drug discovery.

T K Sawyer1.   

Abstract

Src homology-2 (SH2) domains and their associated catalytic or noncatalytic proteins constitute critical signal transduction targets for drug discovery. Such SH2 proteins are found in the regulation of a number of cellular processes, including growth, mitogenesis, motility, metabolism, immune response, and gene transcription. From the relationship of tyrosine phosphorylation and intracellular regulation by protein-tyrosine kinases (PTKs) and protein-tyrosine phosphatases (PTPs), the dynamic and reversible binding interactions of SH2 domain containing proteins with their cognate phosphotyrosine (pTyr) containing proteins provide a third dimensionality to the orchestration of signal transduction pathways that exist as a result of pTyr formation, degradation, and molecular recognition events. This review highlights several key research achievements impacting our current understanding of SH2 structure, mechanisms, and drug discovery that underlie the role(s) of SH2 domains in signal transduction processes, cellular functions, and disease states.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9817027     DOI: 10.1002/(SICI)1097-0282(1998)47:3<243::AID-BIP4>3.0.CO;2-P

Source DB:  PubMed          Journal:  Biopolymers        ISSN: 0006-3525            Impact factor:   2.505


  23 in total

Review 1.  Structural basis for the selective permeability of channels made of communicating junction proteins.

Authors:  Jose F Ek-Vitorin; Janis M Burt
Journal:  Biochim Biophys Acta       Date:  2012-02-10

2.  Structural basis for the interaction between the growth factor-binding protein GRB10 and the E3 ubiquitin ligase NEDD4.

Authors:  Qingqiu Huang; Doletha M E Szebenyi
Journal:  J Biol Chem       Date:  2010-10-26       Impact factor: 5.157

3.  Design and synthesis of phosphotyrosine peptidomimetic prodrugs.

Authors:  Hugo Garrido-Hernandez; Kyung D Moon; Robert L Geahlen; Richard F Borch
Journal:  J Med Chem       Date:  2006-06-01       Impact factor: 7.446

4.  Mathematical models of the VEGF receptor and its role in cancer therapy.

Authors:  Tomás Alarcón; Karen M Page
Journal:  J R Soc Interface       Date:  2007-04-22       Impact factor: 4.118

5.  Conformationally constrained peptidomimetic inhibitors of signal transducer and activator of transcription. 3: Evaluation and molecular modeling.

Authors:  Pijus K Mandal; Donald Limbrick; David R Coleman; Garrett A Dyer; Zhiyong Ren; J Sanderson Birtwistle; Chiyi Xiong; Xiaomin Chen; James M Briggs; John S McMurray
Journal:  J Med Chem       Date:  2009-04-23       Impact factor: 7.446

6.  Stability and peptide binding specificity of Btk SH2 domain: molecular basis for X-linked agammaglobulinemia.

Authors:  S R Tzeng; M T Pai; F D Lung; C W Wu; P P Roller; B Lei; C J Wei; S C Tu; S H Chen; W J Soong; J W Cheng
Journal:  Protein Sci       Date:  2000-12       Impact factor: 6.725

Review 7.  Targeting SH2 domains in breast cancer.

Authors:  Pietro Morlacchi; Fredika M Robertson; Jim Klostergaard; John S McMurray
Journal:  Future Med Chem       Date:  2014       Impact factor: 3.808

8.  Efficient delivery of cell impermeable phosphopeptides by a cyclic peptide amphiphile containing tryptophan and arginine.

Authors:  Amir Nasrolahi Shirazi; Rakesh Kumar Tiwari; Donghoon Oh; Antara Banerjee; Arpita Yadav; Keykavous Parang
Journal:  Mol Pharm       Date:  2013-04-15       Impact factor: 4.939

9.  Structural and functional studies of STAT1 from Atlantic salmon (Salmo salar).

Authors:  Astrid Skjesol; Tom Hansen; Cheng-Yin Shi; Hanna L Thim; Jorunn B Jørgensen
Journal:  BMC Immunol       Date:  2010-03-30       Impact factor: 3.615

10.  A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis.

Authors:  Edmond J Auzenne; Jim Klostergaard; Pijus K Mandal; Warren S Liao; Zhen Lu; Fengqin Gao; Robert C Bast; Fredika M Robertson; John S McMurray
Journal:  J Exp Ther Oncol       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.